Current research offers accumulating knowledge on the molecular pathways implicated in carcinogenesis, enabling the molecular profiling of tumors. Thus, modern medicine facilitates the precise assessment of malignant diseases, predicting tumor behavior and designating specialized treatment strategies. Additionally, information regarding possible drug resistance can be retrieved on tumor samples or using circulating biomarkers, assessed through minimally invasive procedures. Such an approach on the tumor cells' molecular signature should modify and increase the effectiveness of therapeutic interventions.
The aim of this special issue is to highlight the use of circulating biomolecules for predicting the clinical behavior and mainly defining drug resistance of malignant tumors.